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Background: Hypersensitivity reactions to anaesthetic agents are rare but often severe, with a mortality ranging
from 4 to 9% in IgE-mediated events. Identification of the risk factors may contribute to limit the incidence of these
reactions. The aim of our study was to search for possible risk factors of severe perioperative hypersensitivity reactions
in our study population.
Methods: For this study we retrospectively reviewed data from 193 patients who experienced drug hypersensitivity
reactions during general anaesthesia. The diagnostic protocol consisted of 1) history of the reaction, 2) measurement of
serum baseline tryptase and specific IgE-assays for latex, beta-lactams and succinylcholine, 3) skin tests for the agents
listed in the anaesthesia chart and for others likely to be safe for future use, latex, and others medications administered
during the perioperative period (i.e. antibiotics), 4) subdivision of our patients on the basis of two criteria: a) grade
of severity of clinical reactions according to the Ring and Messmer classification; b) results of skin tests and/or
serum specific IgE-assays.
Results: One hundred of 193 patients had reactions of grade I, 32/193 patients had reactions of grade II, 55/193
patients had reactions of grade III and 6/193 patients had reactions of grade IV. A diagnosis of IgE-mediated reaction
was established in 55 cases (28.50%); the most common causes were neuromuscular blocking agents, followed by latex
and beta-lactams. Severe reactions were associated with older age (p = 0.025), asthma (p = 0.042), history of hypertension
(p = 0.001), intake of serum angiotensin converting enzyme inhibitor medication (p = 0.012) or serum angiotensin
II antagonist (p = 0.033), higher levels of basal tryptase (p = 0.0211). Cardiovascular symptoms (p = 0.006) and history of
hypersensitivity to antibiotics (p = 0.029) were more frequently reported in IgE-mediated reactions.
Conclusions: We confirmed the relevance of several clinical features as risk factors for anaphylactic reactions induced
by anaesthetic agents: older age, asthma, hypertension and antihypertensive drugs. We observed increased levels of
serum basal tryptase in severe reactions: this finding may signify that this biomarker is useful for the identification of
patients at risk.
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Severe hypersensitivity reactions observed during gen-
eral anaesthesia are among the most frequent forms of
drug-induced anaphylactic reactions as recently shown
in studies from Australia [1], UK [2] and USA [3]. The
incidence of immediate allergic reactions during general
anaesthesia has been reported between 1 in 20000 and 1
in 10000, with a mortality rate ranging from 3 to 9%, de-
pending on the country [4]. In an Australian study [1],
the main cause of 112 anaphylaxis fatalities was drug al-
lergy: this was the only trigger showing a definite in-
crease in the observation period. When the culprit drug
was specified, anaesthetic agents were identified as the
second most common cause in 64 deaths attributable to
medication (5/64) [1]. In a French survey [5] conducted
between 1997 and 2004, 2516 reactions were reported,
with an estimated incidence of IgE-mediated reactions of
100/million procedures and a female predominance in
adults. The distinction between allergic and non-allergic
forms was made on the basis of diagnostic tests [6].
Clinical manifestations were more severe in IgE-mediated
than in non–IgE-mediated reactions. Neuromuscular
blocking agents (NMBAs) were the most common cause
of these events. General risk factors identified for drug-
induced anaphylaxis fatalities [1] were age 55 to 85 years,
the coexistence of cardiovascular or respiratory diseases
and the exposure to antibiotics or anaestethic agents. The
only risk factor specifically identified for immediate peri-
operative anaphylactic reactions was a previous history of
adverse reaction after exposure to general anaesthetics;
there was no association between IgE mediated reactions
and asthma, atopy, drug hypersensitivity in general or pre-
vious exposure to anaesthetics [5]. On the contrary, allergic
reactions to Hymenoptera stings, angiotensin converting
enzyme (ACE) inhibitors, male sex, serum tryptase levels
above 5 ng/mL [7] and systemic mastocytosis [8] were
identified as risk factors of anaphylaxis. In food allergy an
association between type and severity of pre-existing aller-
gic disease and clinical features of anaphylaxis was also ob-
served: an obstruction of the upper airways was more
frequent in patients with non-controlled allergic rhinitis,
while the lower airways were often affected in the presence
of severe extrinsic asthma; cardiovascular system was in-
volved mostly in patients with severe and widespread ec-
zema [9]. Asthma was considered a major risk factor for
fatal food-induced anaphylaxis [10,11]. It has been reported
that all anaphylactic reactions induced from any trigger oc-
curred more often and more severely in patients affected
by non-controlled allergic rhinitis, eczema, and to a greater
extent by asthma, COPD [9,12] and other respiratory dis-
eases, cardiovascular diseases [13], systemic mastocytosis
and/or other mast cell-related disorders [14-16] and on
therapy with ACE-inhibitors [17]. The purpose of our
study was to identify predisposing factors to perioperativeanaphylaxis. To this aim we associated several clinical and
laboratory parameters with the grade of severity of docu-
mented hypersensitivity reactions occurring during surgical
procedures in a population of patients referred to our
center.
Methods
Patients
Patients with perioperative hypersensitivity reactions
We collected retrospective data from all of the patients
with a history of hypersensitivity perioperative reactions
referred to our allergy clinic during the period January 1,
2010 - May 31, 2014. We adopted a standardised proto-
col including detailed clinical history of the reaction,
skin tests (skin prick test and intradermal testing),
in vitro tests when available (i.e. specific serum IgE to
latex, succinylcholine and beta-lactams). In 66 out of
193 patients basal serum tryptase levels were deter-
mined. Skin testing was performed according to pub-
lished guidelines [4,18]. All of the patients were enrolled
after signing an informed consent to the collection of
their clinical and laboratory data. For all the selected
patients, the association between the risk of severe
hypersensitivity reactions in general anaesthesia and
age, asthma and other respiratory diseases, antihyper-
tensive medication, basal serum tryptase, gender, atopy,
history of reactions to non-steroidal anti-inflammatory
drugs (NSAIDs) or antibiotics, allergic contact dermatitis,
urticaria, thyroid diseases and diagnosis of IgE-mediated
reactions to general anaesthetics was evaluated by a statis-
tical analysis.
In vivo tests
Skin tests procedures
All of the patients underwent skin tests for the drugs
listed in the anaesthetic record, as well as for latex and
other medications or products administered during the
perianesthetic period [4], when available.
Anaesthetic drugs Immediate hypersensitivity reactions
to anaesthetic drugs were investigated using skin prick
tests (SPTs) and intradermal tests (IDTs) with commer-
cial solutions that were performed according to the rec-
ommendations of the Société Française d’Anesthésie et de
Réanimation and the Société Française d’Allergologie ap-
proved by the members of the European Network for
Drug Allergy (ENDA) [4]. Briefly, drugs were tested on
the volar forearm at the concentrations normally unable
to induce localized skin irritation, to minimize the false-
positive results. We used 0.9% saline control as negative
control and histamine 10 mg/mL as a positive control.
SPTs were read after 20 minutes and were considered
positive when a wheal diameter at least half the diameter
of the positive control or 3 mm greater than the negative
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were negative. A bleb of up to 4 mm in diameter was
produced injecting into the dermis 0.02 to 0.05 mL of
the drug at different dilutions. A positive result consisted
in a persistent, often pruritic, erythematous wheal after
20 minutes, the diameter of which was at least twice that
of the post-injection bleb. The anaesthetics agents were
tested at the concentrations listed in Table 1 [4].
Beta-lactam drugs Investigation for beta-lactams allergy
was performed as reported in the ENDA position state-
ment [19].
Latex SPT for latex was performed using standardized
commercial natural rubber latex extract from two manu-
facturers (Alk Abello®, Hørsholm, Denmark; Staller-
gènes®, Antony, Hauts-de-Seine, France) as reported
above for anaesthetic drugs.
In vitro tests
Tryptase
Serum basal tryptase (sBT) was measured with an immu-
nofluorimetric assay by the ImmunoCAP System (Phadia,
now Thermo Fisher Scientific, Uppsala, Sweden). A meas-
urement of tryptase level was performed for all of the pa-
tients during an asymptomatic period, at least 6 weeks
after the last anaphylactic/systemic allergic event. The cut-
off value of tryptase was considered to be ≥5 ng/mL, ac-
cording to the in house reference obtained from a sample
of hundreds of healthy volunteer subjects resident in
Northern Italy as recommended by manufacturer.
Serum specific IgE
The presence of specific IgE antibodies to latex, suc-
cinylcholine, penicilloyl V, G, ampicilloyl, amoxicilloylTable 1 Concentrations of anaesthetic agents tested
Available agents Skin Prick Test Intradermal Tests
mg/mL Dilution mg/mL Dilution mcg/mL
Atracurium 10 1/10 1 1/1000 10
Cisatracurium 2 Undiluted 2 1/100 20
Mivacurium 2 1/10 0.2 1/1000 2
Pancuronium* 2 Undiluted 2 1/10 200
Rocuronium 10 Undiluted 10 1/200 50
Succinylcholine 50 Undiluted 50 1/500 100
Vecuronium 4 Undiluted 4 1/10 400
Midazolam 5 Undiluted 5 1/10 500
Propofol 10 Undiluted 10 1/10 1000
Thiopental 25 Undiluted 25 1/10 2500
Ketamine 10 1/10 10 1/10 1000
Fentanyl 0.05 Undiluted 0.05 1/10 5
(*) untested because unavailable since 2012and cefaclor (normal value ≤ 0.10 IgE kUA/L) were de-
termined using the ImmunoCAP System (Phadia, now
Thermo Fisher Scientific, Uppsala, Sweden) in accord-
ance with the manufacturer’s instructions.
Diagnosis and severity grading
In this retrospective analysis, immediate IgE-mediated
hypersensitivity reactions were diagnosed according with
skin tests and/or IgE assay results consistent with the
clinical history [20]. The severity of reactions was graded
retrospectively using the four classes scale adapted from
Ring and Messmer [21].
Statistical analysis
All of the collected variables were analysed with the
usual descriptive methods: continuous variables were de-
scribed by mean and standard deviation or by median
and range, based on their distribution (checked by visual
inspection of the histogram and – in the case – also by
the Shapiro-Wilk test), while categorical variables were
described by relative and absolute frequency tables.
Cross-tabulations between categorical variables were
analysed by the Fisher’s exact test. The differences of
continuous variables with respect to the reaction’s sever-
ity were analysed by two-sided Student’s t test (in the
case, with the Welch’s correction for different variances),
or Mann–Whitney U test. The one-way ANOVA,
followed (if case of significant F test) by Sidak pairwise
comparisons was used to evaluate the differences between
continuous variables among more than two groups.
The continuous variables of interest, as well as the
possible confounders such as age and sex, were then fit-
ted as independent regressors in a set of logistic models,
using the Wald’s test to verify the significance of each
regressor, as well as the likelihood ratio test to check the
significance of the model as a whole; in these logistic re-
gressions the reaction severity was taken into account as
dependent binary variable. To obtain reliable cutoffs of
some continuous variables, the receiver operating char-
acteristics (ROC) curve analysis was carried out, and the
Youden’s method was used to choose for the optimal
cutpoints.
Statistical significance was assumed for p < 0.05; all
calculations were carried out using the Stata/SE 13.1
statistical package.
Results
Patients
A total of 193 patients (71 males and 122 females, mean
age 37.5 ± 20.8 years) with peri-operative hypersensitivity
reactions during general anaesthesia were included in
this retrospective observational cohort study. A summary
of patients’ demographic and clinical data are shown in
Table 2. A total of 100/193 patients (51.81%; 39 males and
Table 3 Positivity to NMBAs skin tests
NMBAs Patients exposed during
anaesthesia (F/M)
Positivity to skin test in
patients exposed (F/M)
Vecuronium 22 (13/9) 4 (3/1)
Atracurium 18 (12/6) 3 (2/1)
Cisatracurium 23 (13/10) 1 (1/0)
Rocuronium 19 (15/4) 1 (1/0)
Mivacurium 8 (4/4) 0
Pancuronium 3 (2/1) 0
Succinylcholine 15 (11/4) 0
NMBAs: Neuromuscular Blocking Agents, F: female, M: male
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(16.58%; 12 males and 20 females) had grade II reactions,
55/193 patients (28.49%; 20 males and 35 females) had
grade III reactions, and 6/193 patients (3.10%; only fe-
males) had grade IV reactions. For the statistical analysis,
the patients were further classified into two groups: group
0 consisting of 132/193 patients (68.40%) (mean age:
35.16 ± 19.58 years) with grade I and II and group 1 con-
sisting of 61/193 patients (31.60%) (mean age: 42.56 ±
22.64 years) with grade III and IV reactions. NMBAs skin
tests were performed in 130/193 patients (67.35%, 47
males and 83 females, mean age 38.95 ± 20.49 years), and
they were positive in 27/130 patients (20.76%). In each of
the 130 cases, the severity group of the reaction was 0
(grade I + II) in 85/130 patients (65.38%) and 1 (grade III +
IV) in 45/130 patients (34.61%). The respective contribu-
tion of each neuromuscular blocking drug is shown in
Table 3. We carried out skin tests with five different
NMBAs, as cross-reactions occurs commonly among these
drugs, in order to identify a safe alternative agent for subse-
quent anaesthesia. We did not report our cross-reactivity
results because of the small number of positive skin tests
to NMBA in our patients. Serum measurements of suc-
cinylcholine specific IgE levels were performed in 14/16
patients (87.5%) who were exposed to this agent duringTable 2 Demographic and clinical characteristics of
patients with a history of reaction during general
anaesthesia
n %
No. of patients 193
Age (y), mean (range) 37.5 (2–84)
Sex (F/M) 122/71
Personal history of allergic disease 84 43.52
Severity of reaction
Grade I (F/M) 100 (61/39) 51.81
Grade II (F/M) 32 (20/12) 16.58
Grade III (F/M) 55 (35/20) 28.49
Grade IV (F/M) 6 (6/0) 3.10
Concomitant diseases
Asthma 37 19.17
Other respiratory diseases 10 5.18
Hypertension 30 15.54
Thyroid diseases 13 6.73
Chronic urticaria 13 6.73
Anti-hypertensive agents
ACE-inhibitors 14 7.25
ARBs 9 4.66
Beta-blockers 13 6.73
No.: number, ACE: angiotensin converting enzyme, ARBs: angiotensin II
receptor blockersgeneral anaesthesia; all of the patients were negative. Skin
tests with other anaesthetic agents, as reported in Table 4,
were positive in 3 patients for ketamine, and in 1 patient
for atropine. SPTs to latex were positive in 6/193 patients
(3.10%). Serum specific latex-IgE assay was positive in 16/
68 patients (23.52%). Investigations for beta-lactams allergy
were positive in 11/89 patients (12.35%).
Allergic diagnostic work-up
At the end of the allergy work-up, a diagnosis of IgE-
mediated hypersensitivity reaction was established in 55
cases (28.50%), the remaining 138 cases (71.50%) were
considered as non-IgE-mediated reactions. The different
clinical symptoms of IgE- and non IgE-mediated reactions
observed during general anaesthesia are reported in
Table 5. In our group clinical expression was not more se-
vere in patients with a documented IgE-mediated reac-
tions to general anaesthetics (OR: 0.906, CI95%: 0.519 to
1.581; Wald’s test: p = 0.729). However, cardiovascular
symptoms (bradycardia, hypotension, cardiovascular col-
lapse, cardiac arrest) reported in 29/193 patients (15.03%),
were more frequent in IgE-mediated reactions (27.27% vs
10.14%; Fisher’s exact test: p = 0.006). No significant differ-
ence was observed between IgE- and non-IgE-mediated
reactions as regards mucocutaneous symptoms (erythema,
or urticaria, or angioedema) (67.27% vs 74.63%; Fisher’s
exact: p = 0.372). Bronchospasm was recorded more oftenTable 4 Skin test results to agents other than NMBAs
involved in hypersensitivity reactions during anaesthesia
Drugs Positive skin tests (%) No. of patients tested
Beta-lactams 4 (8.16) 49
Penicillin 1 (2.04)
Cephalosporin 3 (6.12)
Hypnotics 8
Ketamine 3 (37.50)
Others 87
Atropine 1 (1.14)
Latex 6 (3.10) 193
NMBAs: Neuromuscular Blocking Agents
Table 5 Patients’ distribution according to clinical symptoms and to mechanism of hypersensitivity reactions during
anaesthesia
Symptoms group IgE-mediated hypersensitivity No. of patients P value
Mucocutaneous 0 1
0 35 (25.36%) 18 (32.72%) 53 0.372
1 103 (74.63%) 37 (67.27%) 140
Cardiovascular 0 1
0 124 (89.86%) 40 (72.73%) 164 0.006
1 14 (10.14%) 15 (27.27%) 29
Bronchospasm 0 1
0 97 (70.29%) 34 (61.82%) 131 0.010
1 41 (29.71%) 21 (38.18%) 62
No. of patients 138 55 193
0 = absent 1 = present
Mucocutaneous: erythema and/or urticarial and/or angioedema
Cardiovascular: hypotension and/or cardiovascular collapse and/or cardiac arrest
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exact test: p = 0.010), but not in IgE-mediated reactions in
particular (38.18% vs. 29.71%; Fisher’s exact test: p = 0.306).
History of hypersensitivity to antibiotics (OR: 2.024,
CI95%: 1.076 to 3.807; Wald’s test: p = 0.029) was more
common in IgE- than in non IgE-mediated reactions.
No significant differences were observed between
the two groups (IgE- and non-IgE-mediated reactions)
as regards age (OR: 0.999, CI95%: 0.984 to 1.014;
Wald’s test: p = 0.912), sex (OR: 0.682, CI95%: 0.363
to 1.280; Wald’s test: p = 0.234), atopy (OR: 0.956,
CI95%: 0.776 to 1.177; Wald’s test: p = 0.675), asthma
(OR: 0.701, CI95%: 0.308 to 1.599; Wald’s test: p =
0.400) and other respiratory diseases (OR: 0.989,
CI95%: 0.246 to 3.969; Wald’s test: p = 0.988), allergic
contact dermatitis (OR: 0.511, CI95%: 0.140 to 1.869;
Wald’s test: p = 0.311), urticaria (OR: 2.093, CI95%:
0.671 to 6.527; Wald’s test: p = 0.203), therapy with
beta-blockers (OR: 1.485, CI95%: 0.464 to 4,751;
Wald’s test: p = 0.504), ACE-inhibitors (OR: 1.817,
CI95%: 0.600 to 5.496; Wald’s test: p = 0.290) or ARBs
(OR: 1.154, CI95%: 0.278 to 4.783; Wald’s test: p =
0.843), thyroid diseases (OR: 1.485, CI95%: 0.464 to
4.751; Wald’s test: p = 0.504), serum tryptase values at
baseline (measured in 66/193 patients) (OR: 0.830,
CI95%: 0.648 to 1.064; Wald’s test: p = 0.143), and
previous adverse reactions to NSAIDs (OR: 1.164,
CI95%: 0.579 to 2.341; Wald’s test: p = 0.669).
Risk factors
We looked for risk factors of severe allergic reactions
(i.e. grade III and IV) during the perioperative period:
1. Age. Each additional year of age increased the risk of
severe reaction by 1.7% (OR: 1.017, CI95% :1.002 to
1.032; Wald’s test: p = 0.025)2. Asthma and antihypertensive medication. A significant
association was observed between the development
of a severe reaction during the general anaesthesia
and history of asthma (OR: 2.144, CI95%: 1.028 to
4.471; Wald’s test: p = 0.042) and ongoing treatment
with ACE inhibitors (OR: 4.326, CI95%: 1.383 to
13.530; Wald’s test: p = 0.012) or ARBs (OR: 4.703,
CI95%: 1.134 to 19.498; Wald’s test: p = 0.033).
Hypertension was significantly more frequent in
patients of group 1 (severity grade III + IV) than in
patients of group 0 (severity grade I + II) (29.51% vs.
9; Fisher’s exact test: p = 0.001).
3. Basal tryptase: sBT tryptase levels were measured in
66/193 patients: values ranged from 1.5 to 14.5 ng/
mL (mean 4.73 ± 2.54 μg/L); 39/66 patients (59.09%)
belonged to group 0 (severity grade I + II), and 27/66
patients (40.91%) to group 1 (severity grade III + IV).
No patient had sBT levels above 20 ng/ml, a minor
diagnostic criteria for mastocytosis. There was a
significant association between sBT and hypertension:
any unitary increase of sBT levels resulted in an increase
in the odds of suffering from hypertension by 30%
(OR:1.296, CI95%: 1.023 to 1.643; Wald’s test: p =
0.032). In addition, when we randomly extracted two
subjects, one with hypertension, and one without, we
found a 74.2% probability that the first patient showed
higher sBT concentrations (Mann–Whitney U test: p =
0.004). Furthermore, by one-way ANOVA we found
that sBT values increased significantly in the grade
of severity of reactions from grade I to grade III (F
test: p = 0.021), with Sidak pairwise test respectively
giving p = 0.140 (I vs. II), p = 0.694 (I vs. III) and
p = 0.017 (II vs. III). Grade IV was not considered
in this analysis because of the limited number of
patients. This finding was confirmed from the ob-
servation that sBT values were significantly higher
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5.62 ± 3.14; range: 1.5-14.5) than in patients of group
0 (severity grade I + II) (mean: 4.11 ± 1.83; range: 1.5-
9.4) (Welch’s test: p = 0.0304) (Figure 1). In this sub-
group of patients age did not affect the severity of the
reaction (OR: 1.023; CI95%: 0.996 to 1.050; Wald’s
test: p = 0.102).
No effect on symptom severity was observed as
regards sex (OR: 1.306, CI95%: 0.689 to 2.477, Wald’s
test: p = 0.412), atopy (OR: 0.949, CI95%: 0.762 to 1.181;
Wald’s test: p = 0.640), history of hypersensitivity to
NSAIDs (OR: 0.777; CI95%: 0.381 to 1.584; Wald’s test:
p = 0.489) or antibiotics (OR: 0.984; CI95%: 0.533 to
1.816; Wald’s test: p = 0.960), allergic contact dermatitis
(OR: 0.974, CI95%: 0.323 to 2.936; Wald’s test: p =
0.963), other respiratory diseases (OR: 3.43, CI95%:
0.932 to 12.662; Wald’s test: p = 0.064), urticaria (OR:
0.943, CI95%: 0.278 to 3.193; Wald’s test: p = 0.925),
therapy with beta-blockers (OR: 1.916, CI95%: 0.615 to
5.968; Wald’s test: p = 0.262), thyroid diseases (OR:
1.361, CI95%: 0426 to 4.348; Wald’s test: p = 0.602). Fur-
thermore, we did not find a significant association be-
tween sensitization to NMBAs and the following
variables: sex (15.49% vs 13.11%; Fisher’s exact test: p =
0.671), higher grade of severity of the reaction (11,48%
vs 15,15%; Fisher’s exact test: p = 0.656), asthma (10.81%
vs 14.74%; Fisher’s exact test: p = 0.792), history of
hypersensitivity to NSAIDs and/or antibiotics (16.07% vs
11.11%; Fisher’s exact test: p = 0.403), atopy (11.90% vsFigure 1 Basal serum tryptase levels and hypersensitivity reaction sev
standard deviation between group 1 (severity grade III + IV) and group 0 (s14.95%; Fisher’s exact test: p = 0.672), age (OR: 0.989,
CI95%: 0.969 to 1.009; Wald’s test: p = 0.308), therapy
with ACE-inhibitors (14.29% vs 13.97%; Fisher’s exact
test: p > 0.999), ARBs (0% vs 14.67%; Fisher’s exact test:
p = 0.365), or beta-blockers (15.38% vs 13.89%; Fisher’s
exact test: p > 0.999), allergic contact dermatitis (3.70%
vs 96.30%; Fisher’s exact test: p = 0.704). We observed a
nearly significant association between allergy to latex
and history of food allergy (14.29% vs 4.29%; Fisher’s
exact test: p = 0.059).
Discussion
In our study we looked for risk factors of severe adverse
reactions in patients with history of perioperative hyper-
sensitivity. A main finding of our study was that older
patients were confirmed to be affected by more severe
hypersensitivity reactions during general anaesthesia in
comparison with younger subjects. Previous studies
identified older patients as being at risk of severe and
fatal anaphylaxis, in particular for reactions induced by
drugs and Hymenoptera venom [2,22,1,13,7,23,24,3].
The higher risk of severe reaction or demise with respect
to increasing age has already been reported [13,23,24]
and has been attributed to cerebrovascular or cardiovascu-
lar diseases, capable of reducing the patients’ ability to tol-
erate some complications of anaphylaxis (i.e. hypotension,
hypoxia and arrhythmia) or the adverse effects of the
treatment in the presence of these conditions. An alterna-
tive explanation was the exposure to consecutive triggers
such as drugs [24]. A second important finding was aerity in general anaesthesia: Mean basal serum tryptase values ±
everity grade I + II).
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cardiovascular diseases as asthma and hypertension and
the severity of perioperative reactions as previously re-
ported in literature in different allergic conditions
[2,13,24]. Bronchospasm has been a major component of
fatal reactions in children and of most fatalities due to
food allergy [2] and asthma was more common in patient
with food related anaphylaxis [3]. The significance of car-
diovascular diseases as risk factors for severe clinical
manifestation was also consistent with the observation
reported above i.e. older adults may be at greater risk
of exposure to medications triggering anaphylactic reac-
tions. We pointed out hypertension as a risk factor inde-
pendent from the use of antihypertensive drugs. However
ACE inhibitors and ARBs were also significantly associated
with the risk of anaphylaxis during general anaesthesia; the
role of these drugs as facilitating factors of severe anaphyl-
axis has already been discussed by other authors especially
as regards ACE inhibitors [7,17,24,25]. To our knowledge,
this is the first investigation evaluating the behavior of sBT
as a predictor of severe reactions in patients with peri-
operative hypersensitivity. We found that higher levels of
sBT were associated with more severe clinical symptoms
in IgE- and non IgE-mediated reactions observed during
general anaesthesia. Furthermore our data set on sBT have
shown that a value > 4.9 ng/mL gives a sensitivity and a
positive predictive value (PPV) of 59.3% in hypersensitivity
during general anaesthesia, but more studied are needed to
improve the cutoff value. Nevertheless this result con-
firmed previous findings in anaphylaxis induced by differ-
ent agents, as Hymenoptera venom [7], in which a sBT
value of about 5 ng/mL clearly increased the odds ratio of
severe systemic reactions. We found a significant associ-
ation between sBT values and hypertension: a possible ex-
planation was an increase of sBT in cardiovascular diseases
[26,27]. We found that the association of sBT level with
the severity of reactions was not influenced by patients’ age
in spite of the previously described increase of serum levels
of this mediator in older subjects [28,29]. Until now serum
tryptase has proved useful as a diagnostic tool of anaphyl-
actic events during general anaesthesia during the acute
phase with a value >25 ng/mL [4,30]. This threshold was
associated with a definite increase of total tryptase in the
acute event and not with a false positive value due to un-
apparent mastocytosis. In our study we observed for the
first time that sBT can be used as a screening tool to iden-
tify patients at risk of anaphylaxis in the perioperative
period. We did not confirm an association between IgE-
mediated reactions and the severity of all symptoms re-
ported from our patients as found in other studies [5,30].
Nonetheless, we found that cardiovascular symptoms, the
index of the most severe reactions according to Ring and
Messmer classification, were significantly more frequent in
patients with IgE-mediated reactions.Conclusions
In summary our study confirmed the relevance of
several clinical features as risk factors of anaphylactic
reactions induced by anaesthetic agents: older age,
asthma, hypertension and antihypertensive drugs. We
observed increased levels of serum basal tryptase in
severe reactions: this finding may signify that this
biomarker is useful for the identification of patients
at risk.
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